(34.226.234.102) 您好!臺灣時間:2021/05/12 10:32
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果

詳目顯示:::

我願授權國圖
: 
twitterline
研究生:許曼蓉
研究生(外文):Man-Jung
論文名稱:桑椹多酚調節肝臟脂肪之作用
論文名稱(外文):Mulberry Polyphenolic Components Reduce Hepatic Lipid Accumulation via Inhibiting Lipogenesis and Promoting Hepatic Cleareance
指導教授:王朝鐘王朝鐘引用關係
指導教授(外文):Chau-Jong Wang
學位類別:碩士
校院名稱:中山醫學大學
系所名稱:生化暨生物科技研究所
學門:生命科學學門
學類:生物科技學類
論文種類:學術論文
論文出版年:2010
畢業學年度:98
語文別:中文
論文頁數:94
相關次數:
  • 被引用被引用:0
  • 點閱點閱:275
  • 評分評分:系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔系統版面圖檔
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:1
過多的脂肪堆積在肝臟中,輕者會造成脂肪肝,重者還會導致脂肪性肝臟發炎(steatohepatitis)、肝臟纖維化(liver fibrosis)及肝硬化(liver cirrhosis)。而脂肪肝又會牽涉到許多代謝疾病(metabolic syndrome),如高血壓(hypertension)、高血脂症、高膽固醇症、糖尿病,因此開發具化學預防或治療成分的天然物,嚴然成為目前預防或治療脂肪肝性疾病重要的研究方向。桑椹萃取物已被證實具有降血脂及抗粥狀動脈硬化等疾病之成效,因此本篇欲進一步探討桑椹萃取物對抑制肝臟脂肪堆積是否也有相似之功效。本論文以細胞模式和動物模式探討桑椹萃取物對於減少肝臟脂肪堆積之作用與機制,分別以油酸和高油脂飲食 (high fat diet, HFD) 誘導細胞實驗及動物之肝臟脂肪堆積。結果證實桑椹萃取物確實可降低血液和肝臟脂質 (三酸甘油脂、膽固醇、脂肪酸) 堆積的現象,並使高油脂飲食組動物體重增加情形趨緩。亦發現桑椹萃取物能降低脂質生成酵素及其轉錄因子之表現,例如FAS、ACC、HMGCoR、GPAT、SREBPs等,並使促進脂質代謝酵素及其轉錄因子之表現,如CPTI、PPARα,達到降低肝臟脂質堆積的效果。本研究推論,桑椹萃取物主要是透過AMPK (AMP-activated kinase) 之傳訊路徑調控上述這些蛋白質,達到降低肝臟脂肪堆積之效果。研究結果顯示桑椹萃取物對於開發成為預防及治療脂肪肝的保健食品具有相當的潛力。

Excess fat accumulated in the liver, the lighter will cause fatty liver, the serious one will also cause steatohepatitis, liver fibrosis and liver cirrhosis.
Fatty liver will involve a lot of metabolic syndrome, such as obesity, hypertension, dyslipidemia and diabetes. Therefore, develop the natural thing with chemistry preventing or treatment composition has already become an important direction for treat the fatty liver disease. Mulberry extracts (MWE、MAE and MPE) have been known to reduce blood lipid and prevent atherosclerosis. However, the effects of mulberry extracts on regulating hepatic lipid metabolism are unclear. To better understand the functions and mechanisms of mulberry extracts in reducing hepatic lipid accumulation, the fat overload conditions both in cell culture and an animal experimental model were performed. In this study, mulberry extracts were further confirmed that they could regulate serum and hepatic lipid contents (e.g. triglyceride, cholesterol, and free fatty acid) and reduce the rate of body weight in mice. Furthermore, mulberry extracts also could decrease the expression of lipogenic enzymes, such as FAS, ACC, HMG-CoA reductase, SREBP, GPAT and increase the expression of CPTI and PPARα proteins, which are critical regulators of hepatic lipid metabolism. The results show that mulberry extracts are able to reduce the hepatic lipid accumulation through the AMPK (AMP-activated protein kinase) signaling pathway. These observations suggested that mulberry extracts have potentiality in developing the health food for preventing and remedying fatty liver.


縮寫表 4
中文摘要 5
英文摘要 6
第一章、緒論 7
第二章、研究動機 18
第三章、實驗模式與架構 20
第四章、實驗方法 22
第一部分:細胞實驗 22
第二部分:動物實驗 28
第五章、實驗藥品與器材 32
第六章、試劑配製 36
第七章、結果 39
第八章、討論 51
附圖一 87
附圖二 88
附圖三 89
參考文獻 90


[1]H.P. Huang, Y.W. Shih, Y.C. Chang, C.N. Hung, C.J. Wang, Chemoinhibitory effect of mulberry anthocyanins on melanoma metastasis involved in the Ras/PI3K pathway. J Agric Food Chem 56 (2008) 9286-9293.
[2]盧宏民, 中藥大辭典. (2003) 3016-3018.
[3]J.C. Jeong, S.W. Jang, T.H. Kim, C.H. Kwon, Y.K. Kim, Mulberry fruit (Moris fructus) extracts induce human glioma cell death in vitro through ROS-dependent mitochondrial pathway and inhibits glioma tumor growth in vivo. Nutr Cancer 62 (2010) 402-412.
[4]H.G. Kim, M.S. Ju, J.S. Shim, M.C. Kim, S.H. Lee, Y. Huh, S.Y. Kim, M.S. Oh, Mulberry fruit protects dopaminergic neurons in toxin-induced Parkinson''s disease models. Br J Nutr 104 (2010) 8-16.
[5]P.H. Shih, Y.C. Chan, J.W. Liao, M.F. Wang, G.C. Yen, Antioxidant and cognitive promotion effects of anthocyanin-rich mulberry (Morus atropurpurea L.) on senescence-accelerated mice and prevention of Alzheimer''s disease. J Nutr Biochem 21 (2010) 598-605.
[6]L.K. Liu, F.P. Chou, Y.C. Chen, C.C. Chyau, H.H. Ho, C.J. Wang, Effects of mulberry (Morus alba L.) extracts on lipid homeostasis in vitro and in vivo. J Agric Food Chem 57 (2009) 7605-7611.
[7]L.K. Liu, H.J. Lee, Y.W. Shih, C.C. Chyau, C.J. Wang, Mulberry anthocyanin extracts inhibit LDL oxidation and macrophage-derived foam cell formation induced by oxidative LDL. J Food Sci 73 (2008) H113-121.
[8]A.J. Kim, S. Park, Mulberry extract supplements ameliorate the inflammation-related hematological parameters in carrageenan-induced arthritic rats. J Med Food 9 (2006) 431-435.
[9]E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri, B.R. Bacon, Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 94 (1999) 2467-2474.
[10]P.M. Yang, G.T. Huang, J.T. Lin, J.C. Sheu, M.Y. Lai, I.J. Su, H.C. Hsu, D.S. Chen, T.H. Wang, J.L. Sung, Ultrasonography in the diagnosis of benign diffuse parenchymal liver diseases: a prospective study. Taiwan Yi Xue Hui Za Zhi 87 (1988) 966-977.
[11]E.M. Brunt, Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 21 (2001) 3-16.
[12]J. Ludwig, T.R. Viggiano, D.B. McGill, B.J. Oh, Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55 (1980) 434-438.
[13]C.P. Day, O.F. James, Steatohepatitis: a tale of two "hits"? Gastroenterology 114 (1998) 842-845.
[14]A.J. Sanyal, C. Campbell-Sargent, F. Mirshahi, W.B. Rizzo, M.J. Contos, R.K. Sterling, V.A. Luketic, M.L. Shiffman, J.N. Clore, Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120 (2001) 1183-1192.
[15]J.K. Dowman, J.W. Tomlinson, P.N. Newsome, Pathogenesis of non-alcoholic fatty liver disease. QJM 103 (2010) 71-83.
[16]C. Postic, J. Girard, Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice. J Clin Invest 118 (2008) 829-838.
[17]譚健民, 非酒精性脂肪肝疾病的現代觀:著重於其衍生「肝纖維化」的致病機轉之探討. 台灣醫界 51 (2008) 274-279.
[18]A.M. Zivkovic, J.B. German, A.J. Sanyal, Comparative review of diets for the metabolic syndrome: implications for nonalcoholic fatty liver disease. Am J Clin Nutr 86 (2007) 285-300.
[19]A.W. Alberts, A.W. Strauss, S. Hennessy, P.R. Vagelos, Regulation of synthesis of hepatic fatty acid synthetase: binding of fatty acid synthetase antibodies to polysomes. Proc Natl Acad Sci U S A 72 (1975) 3956-3960.
[20]S.J. Wakil, J.K. Stoops, V.C. Joshi, Fatty acid synthesis and its regulation. Annu Rev Biochem 52 (1983) 537-579 begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting begin_of_the_skype_highlighting              52 (1983) 537-579      end_of_the_skype_highlighting.
[21]R.W. Brownsey, A.N. Boone, J.E. Elliott, J.E. Kulpa, W.M. Lee, Regulation of acetyl-CoA carboxylase. Biochem Soc Trans 34 (2006) 223-227.
[22]P.J. Jones, A.S. Pappu, L. Hatcher, Z.C. Li, D.R. Illingworth, W.E. Connor, Dietary cholesterol feeding suppresses human cholesterol synthesis measured by deuterium incorporation and urinary mevalonic acid levels. Arterioscler Thromb Vasc Biol 16 (1996) 1222-1228.
[23]D.S. Rosser, M.N. Ashby, J.L. Ellis, P.A. Edwards, Coordinate regulation of 3-hydroxy-3-methylglutaryl-coenzyme A synthase, 3-hydroxy-3-methylglutaryl-coenzyme A reductase, and prenyltransferase synthesis but not degradation in HepG2 cells. J Biol Chem 264 (1989) 12653-12656.
[24]J.L. Goldstein, M.S. Brown, Regulation of the mevalonate pathway. Nature 343 (1990) 425-430.
[25]R.A. Coleman, T.M. Lewin, D.M. Muoio, Physiological and nutritional regulation of enzymes of triacylglycerol synthesis. Annu Rev Nutr 20 (2000) 77-103.
[26]L.E. Hammond, P.A. Gallagher, S. Wang, S. Hiller, K.D. Kluckman, E.L. Posey-Marcos, N. Maeda, R.A. Coleman, Mitochondrial glycerol-3-phosphate acyltransferase-deficient mice have reduced weight and liver triacylglycerol content and altered glycerolipid fatty acid composition. Mol Cell Biol 22 (2002) 8204-8214.
[27]T.M. Lewin, N.M. Schwerbrock, D.P. Lee, R.A. Coleman, Identification of a new glycerol-3-phosphate acyltransferase isoenzyme, mtGPAT2, in mitochondria. J Biol Chem 279 (2004) 13488-13495.
[28]J.D. Horton, J.L. Goldstein, M.S. Brown, SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109 (2002) 1125-1131.
[29]L.J. Engelking, H. Kuriyama, R.E. Hammer, J.D. Horton, M.S. Brown, J.L. Goldstein, G. Liang, Overexpression of Insig-1 in the livers of transgenic mice inhibits SREBP processing and reduces insulin-stimulated lipogenesis. J Clin Invest 113 (2004) 1168-1175.
[30]C.Y. Michael R. Briggs, Xiaodong Wang, Michael S. Brown, and Joseph L. Goldstein, Nuclear Protein ThatB inds Sterol Regulatory Elemenot f Low Density
Lipoprotein Receptor Promoter. J. Biol. Chem 268 (1993) 14490-14496.
[31]B. Desvergne, W. Wahli, Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 20 (1999) 649-688.
[32]Y.X. Wang, PPARs: diverse regulators in energy metabolism and metabolic diseases. Cell Res 20 (2010) 124-137.
[33]D.E. Moller, J.P. Berger, Role of PPARs in the regulation of obesity-related insulin sensitivity and inflammation. Int J Obes Relat Metab Disord 27 Suppl 3 (2003) S17-21.
[34]S.V. Pande, R. Parvin, Characterization of carnitine acylcarnitine translocase system of heart mitochondria. J Biol Chem 251 (1976) 6683-6691.
[35]C.H. Britton, R.A. Schultz, B. Zhang, V. Esser, D.W. Foster, J.D. McGarry, Human liver mitochondrial carnitine palmitoyltransferase I: characterization of its cDNA and chromosomal localization and partial analysis of the gene. Proc Natl Acad Sci U S A 92 (1995) 1984-1988.
[36]J.S. Oakhill, J.W. Scott, B.E. Kemp, Structure and function of AMP-activated protein kinase. Acta Physiol (Oxf) 196 (2009) 3-14.
[37]P. Misra, R. Chakrabarti, The role of AMP kinase in diabetes. Indian J Med Res 125 (2007) 389-398.
[38]Y.M. Jeen, S.Y. Jin, [Pathology of nonalcoholic steatohepatitis]. Korean J Hepatol 15 (2009) 122-130.
[39]L. Abenavoli, Metformin: a therapeutic option for treating nonalcoholic fatty liver disease. Dig Dis Sci 55 (2010) 2121.
[40]K. Cusi, Thiazolidinediones in NASH. An odd couple meant to be? J Clin Gastroenterol 43 (2009) 503-505.
[41]A.S. Wierzbicki, D.P. Mikhailidis, R. Wray, M. Schacter, R. Cramb, W.G. Simpson, C.B. Byrne, Statin-fibrate combination: therapy for hyperlipidemia: a review. Curr Med Res Opin 19 (2003) 155-168.
[42]K.K. Kharbanda, S.L. Todero, B.W. Ward, J.J. Cannella, 3rd, D.J. Tuma, Betaine administration corrects ethanol-induced defective VLDL secretion. Mol Cell Biochem 327 (2009) 75-78.
[43]I. Zamin, Jr., A.A. Mattos, A.Z. Mattos, G. Coral, D. Santos, C. Rhoden, The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. Arq Gastroenterol 47 (2010) 86-92.
[44]X. Yang, L. Yang, H. Zheng, Hypolipidemic and antioxidant effects of mulberry (Morus alba L.) fruit in hyperlipidaemia rats. Food Chem Toxicol (2010).
[45]Y. Fujimoto, J. Onoduka, K.J. Homma, S. Yamaguchi, M. Mori, Y. Higashi, M. Makita, T. Kinoshita, J. Noda, H. Itabe, T. Takanoa, Long-chain fatty acids induce lipid droplet formation in a cultured human hepatocyte in a manner dependent of Acyl-CoA synthetase. Biol Pharm Bull 29 (2006) 2174-2180.
[46]M.J. Gomez-Lechon, M.T. Donato, A. Martinez-Romero, N. Jimenez, J.V. Castell, J.E. O''Connor, A human hepatocellular in vitro model to investigate steatosis. Chem Biol Interact 165 (2007) 106-116.
[47]J. Folch, M. Lees, G.H. Sloane Stanley, A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem 226 (1957) 497-509.
[48]P. Dugo, L. Mondello, G. Errante, G. Zappia, G. Dugo, Identification of anthocyanins in berries by narrow-bore high-performance liquid chromatography with electrospray ionization detection. J Agric Food Chem 49 (2001) 3987-3992.
[49]M. Mitcheva, H. Astroug, D. Drenska, A. Popov, M. Kassarova, Biochemical and morphological studies on the effects of anthocyans and vitamin E on carbon tetrachloride induced liver injury. Cell Mol Biol (Noisy-le-grand) 39 (1993) 443-448.
[50]B. Ren, A.P. Thelen, J.M. Peters, F.J. Gonzalez, D.B. Jump, Polyunsaturated fatty acid suppression of hepatic fatty acid synthase and S14 gene expression does not require peroxisome proliferator-activated receptor alpha. J Biol Chem 272 (1997) 26827-26832.
[51]C.L. Lin, H.C. Huang, J.K. Lin, Theaflavins attenuate hepatic lipid accumulation through activating AMPK in human HepG2 cells. J Lipid Res 48 (2007) 2334-2343.
[52]X. Hou, S. Xu, K.A. Maitland-Toolan, K. Sato, B. Jiang, Y. Ido, F. Lan, K. Walsh, M. Wierzbicki, T.J. Verbeuren, R.A. Cohen, M. Zang, SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 283 (2008) 20015-20026.
[53]C.L. Hsu, S.L. Huang, G.C. Yen, Inhibitory effect of phenolic acids on the proliferation of 3T3-L1 preadipocytes in relation to their antioxidant activity. J Agric Food Chem 54 (2006) 4191-4197.
[54]C.L. Hsu, W.H. Lo, G.C. Yen, Gallic acid induces apoptosis in 3T3-L1 pre-adipocytes via a Fas- and mitochondrial-mediated pathway. J Agric Food Chem 55 (2007) 7359-7365.
[55]C.L. Hsu, C.H. Wu, S.L. Huang, G.C. Yen, Phenolic compounds rutin and o-coumaric acid ameliorate obesity induced by high-fat diet in rats. J Agric Food Chem 57 (2009) 425-431.
[56]M. Furuhashi, G. Tuncman, C.Z. Gorgun, L. Makowski, G. Atsumi, E. Vaillancourt, K. Kono, V.R. Babaev, S. Fazio, M.F. Linton, R. Sulsky, J.A. Robl, R.A. Parker, G.S. Hotamisligil, Treatment of diabetes and atherosclerosis by inhibiting fatty-acid-binding protein aP2. Nature 447 (2007) 959-965.

QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
系統版面圖檔 系統版面圖檔